---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-004161"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2022-03-18T23:59:59+00:00"
generated_at: "2026-06-26T21:46:43.051622+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Janux reports FY2021 net loss $32.7M; cash $375M; IND filings for two TRACTr programs on track for 2022

## Summary
- Cash, cash equivalents and short-term investments $375.0M at Dec 31, 2021, vs $7.8M a year ago.
- Net loss $13.4M for Q4 2021 and $32.7M for FY2021; R&D expense $26.2M (FY2021).
- PSMA-TRACTr IND submission expected H1 2022; EGFR-TRACTr IND expected H2 2022.
- Nominated first TRACIr candidate, a PD-L1xCD28 costimulatory bispecific; IND planned for 2023.
- Appointed Byron Robinson, Ph.D., J.D., as Chief Strategy Officer.

## SEC filing metadata
- accession: 0000950170-22-004161
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2022-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017022004161/0000950170-22-004161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017022004161/janx-20220318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-004161
- JSON: https://secwatch.observer/filing/0000950170-22-004161.json
- Plain text: https://secwatch.observer/filing/0000950170-22-004161.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.